Skip to main content
American Journal of Translational Research logoLink to American Journal of Translational Research
. 2024 Feb 15;16(2):458–465. doi: 10.62347/NLLM5784

Design and clinical application of a risk prediction model for diabetic foot

Xiaoping Yang 1, Shaohong Chen 1, Leiquan Ji 1, Qiaohui Chen 1, Chujia Lin 1
PMCID: PMC10918135  PMID: 38463576

Abstract

Objective: To construct and evaluate a nomogram prediction model for the risk of diabetic foot in patients with type 2 diabetes based on their clinical data, and to assist clinical healthcare professionals in identifying high-risk factors and developing targeted intervention measures. Methods: We retrospectively collected clinical data from 478 hospitalized patients with type 2 diabetes at the First Affiliated Hospital of Shantou University Medical College from January 2019 to December 2021. The patients were divided into a diabetic foot group (n=312) and a non-diabetic foot group (n=166) based on whether they had diabetic foot. The baseline data of both groups were collected. Univariate and multivariate analyses as well as logistic regression analysis were conducted to explore the risk factors for diabetic foot. A nomogram prediction model was established using the package “rms” version 4.3. The model was internally validated using the area under the receiver operating characteristic curve (AUC). Additionally, the decision curve analysis (DCA) was performed to evaluate the performance of the nomogram model. Results: The results from the logistic regression analysis revealed that being male, smoking, duration of diabetes, glycated hemoglobin, hyperlipidemia, and atherosclerosis were influencing factors for diabetic foot (all P<0.05). The AUC of the model in predicting diabetic foot was 0.804, with a sensitivity of 75.3% and specificity of 74.4%. Harrell’s C-index of the nomogram prediction model for diabetic foot was 0.804 (95% CI: 0.762-0.844), with a threshold value of >0.675. The DCA findings demonstrated that the nomogram model provided a net clinical benefit. Conclusion: The nomogram prediction model constructed in this study showed good predictive performance and can provide a basis for clinical workers to prevent and intervene in diabetic foot, thereby improving the overall diagnosis and treatment.

Keywords: Diabetes, diabetic foot, nomogram prediction model, clinical application

Introduction

Diabetes is a common chronic disease worldwide, characterized by insulin deficiency in the blood due to dysfunction of pancreatic islet cells, which in turn affects the body’s ability to utilize glucose and ultimately results in clinical symptoms such as emaciation, polydipsia, polyuria, and polyphagia, severely impacting the patients’ quality of life [1-3]. In addition, as the disease progresses, patients may develop vascular complications, including coronary heart disease, ocular blood flow abnormalities, and lower extremity vascular disease. Among them, distal lower extremity vascular lesions can cause foot ulcers or deep tissue damage, with or without infection [4]. Research has shown that diabetic necrosis is a serious public health problem worldwide [5]. Diabetic foot refers to infections, ulcers, or tissue damage in the feet of diabetic patients, often accompanied by peripheral neuropathy and/or peripheral arterial disease [6]. Severe cases can be challenging to treat, with a high risk of recurrence and potential for limb amputation. Therefore, predicting the risk factors for diabetic foot is of great clinical significance in reducing the incidence of necrosis.

The nomogram prediction model is a type of clinical prognostic prediction model and scoring system. It calculates a total score based on the numerical values of individual predictive variables, which is then used to estimate the risk or probability of a specific clinical event outcome. It has been proven to be effective in predicting the risk of various diseases. Although research on diabetic foot has made progress, considering the regional variations in the prevalence of diabetes and diverse lifestyle habits across different regions, developing specific prediction models for each locality is crucial for improving disease prevention [7,8]. Based on the above theory, this study aims to identify the independent influencing factors associated with diabetic foot and construct a nomogram prediction model, providing more research targets for clinical intervention in diabetic necrosis.

Materials and methods

General data

The clinical data of 478 hospitalized patients with type 2 diabetes at the First Affiliated Hospital of Shantou University School of Medicine from January 2019 to December 2021 were retrospectively collected. The patients were divided into a diabetic foot group (n=312) and a non-diabetic foot group (n=166) based on whether they had diabetic foot (Figure 1).

Figure 1.

Figure 1

Flowchart of the study process.

Inclusion criteria: 1. Patients who met the diagnostic criteria for diabetic foot according to relevant guidelines, including abnormal foot sensation, foot deformities, ischemic pain, difficulty walking, with or without infection, ulcers, and gangrene, and early signs such as decreased skin temperature and pain [9]; 2. Patients with complete clinical data; 3. Patients who were treated for diabetic foot at The First Affiliated Hospital of Shantou University Medical College.

Exclusion criteria: 1. Patients with peripheral vascular diseases caused by other reasons; 2. Patients with previous foot trauma; 3. Patients with abnormal blood glucose levels caused by other diseases; 4. Patients with rheumatic immune diseases requiring medication; 5. Pregnant and lactating women.

The study was approved by the Ethics Committee of the First Affiliated Hospital of Shantou University Medical College.

Data collection

General information of all patients, including gender, age, duration of diabetes, smoking history (≥1 cigarette per day for at least 6 months), alcohol consumption (≥50 mL per day), comorbidities, and body mass index (BMI), were collected through the electronic medical record system.

Hematologic values

Serum indicators were traced back to the first hospitalization of all patients, including glycated hemoglobin, fasting blood glucose, lipid profile (cholesterol, triglycerides, high-density lipoprotein), pancreatic function indicator (C-peptide), liver function indicators (alanine aminotransferase, aspartate aminotransferase), renal function indicators (creatinine, blood urea nitrogen), routine blood indexes, coagulation function indicators, and nutritional indicators (total bile acid, prealbumin, total serum protein).

Before blood collection, patients were instructed to fast and abstain from food, drink, and medication for at least 10 hours. The next morning, 5 ml of fasting blood was collected from each patient. After centrifugation at 3000 rpm for 10 minutes using a TD3WS centrifuge (Xiangmaida, instrument number 20160115), the serum was obtained and analyzed using a fully automated biochemical analyzer, employing oxidase and enzyme methods.

Statistical analysis

All data were analyzed using SPSS 22.0 statistical analysis software. Measured data were expressed as mean ± standard deviation (x̅ ± sd) and compared between groups using independent t-tests. Counted data were expressed as percentages (n/%) and compared using chi-square test. Logistic regression analysis was performed to identify independent risk factors for diabetic foot. Receiver operating characteristic (ROC) curve was plotted to analyze the area under the curve and the optimal cutoff value for each influencing factor, exploring their predictive ability for diabetic foot.

The package “rms” version 4.3 was used to construct a nomogram prediction model for diabetic foot, and the Hosmer-Lemeshow test was carried out to evaluate the goodness of fit of the comprehensive model. Calibration and decision curves were used for internal validation and predictive performance evaluation. A p-value of less than 0.05 was considered significant.

Results

Comparison of baseline characteristics

Our results showed significant differences between the diabetic foot group and the non-diabetic foot group in terms of sex, smoking history, duration of diabetes, hyperlipidemia, and atherosclerosis (all P<0.05). However, there were no significant differences in terms of age, body mass index, hypertension, alcohol history, coronary heart disease, and chronic obstructive pulmonary disease between the two groups (all P>0.05). See Table 1.

Table 1.

Comparison of baseline characteristics between the two groups

Item Diabetic foot group (n=322) Non-diabetic foot group (n=166) t/χ2 P
Gender 5.634 0.018
    Male 199 84
    Female 123 82
Age (years) 65.5±8.4 64.9±8.3 0.751 0.453
Body mass index (kg/m2) 22.7±1.6 23.1±1.5 2.672 0.080
Alcohol history 98 36 3.451 0.063
    Volume (mL/d) 125.6±1.8 124.8±1.7 3.089 0.053
    Time of duration (years) 13.4±4.9 13.8±5.2 0.664 0.077
Smoking history 100 27 12.447 0.000
    Volume (pcs/d) 11.6±3.4 12.0±4.1 0.572 0.091
    Time of duration (years) 25.4±4.3 26.2±3.9 1.889 0.641
Hyperlipidemia 87 14 23.050 0.000
Coronary heart disease 17 5 1.308 0.253
Chronic obstructive pulmonary disease 13 6 0.052 0.820
    Duration (year) 3.23±1.4 3.42±1.3 1.419 0.364
Duration of diabetes (year) 15.8±2.2 13.8±2.4 9.221 0.000
Hypertension 45 23 6.830 0.671
    Duration (year) 6.77±1.91 6.82±1.87 3.556 0.440
Atherosclerosis 71 19 8.188 0.004

Note: t: data from t-test; χ2: data from chi-square test.

Comparison of serum marker levels

There were no significant differences between the two groups in terms of fasting blood glucose, C-peptide, liver function indicators (alanine aminotransferase, aspartate aminotransferase), renal function markers (creatinine, blood urea nitrogen), routine blood indexes, coagulation function markers, and nutritional markers (total bile acid, prealbumin, serum total protein) (all P>0.05). However, there was a significant difference in the glycated hemoglobin level between two groups (P<0.05). See Table 2.

Table 2.

Comparison of serum marker levels between the two groups

Item Diabetic foot group (n=322) Non-diabetic foot group (n=166) t/χ2 P
Fasting blood glucose (mmol/L) 8.84±3.75 8.19±3.38 1.875 0.061
Glycated hemoglobin (%) 9.32±2.20 7.49±2.45 8.371 0.000
Alanine aminotransferase (U/L) 17.34±8.86 17.53±8.71 0.226 0.822
Aspartate aminotransferase (U/L) 14.55±7.33 15.32±8.18 1.056 0.291
Total bile acid (µmol/L) 10.34±3.58 10.37±2.64 0.095 0.924
Prealbumin (mg/L) 253.58±77.79 254.20±66.84 0.087 0.930
Serum total protein (g/L) 65.38±8.34 65.78±7.90 0.511 0.610
Creatinine (µmol/L) 136.55±84.67 131.82±67.65 0.624 0.533
Blood urea nitrogen (mmol/L) 4.92±0.53 4.88±0.56 0.775 0.439
Activated partial thromboplastin time (s) 29.15±5.93 28.78±5.34 0.675 0.500
Prothrombin time (s) 12.24±1.23 12.28±1.85 0.338 0.735
Thrombin time (s) 19.41±2.68 19.28±2.67 0.508 0.611
D-dimer (mg/L) 0.75±0.51 0.83±0.68 1.460 0.145
C-peptide (ng/mL) 2.12±1.48 2.56±2.41 2.491 0.013

Note: t: data from t-test; χ2: data from chi-square test.

Logistic analysis of risk factors for diabetic foot

Univariate analysis revealed that the risk factors for diabetic foot included male, smoking history, duration of diabetes, glycated hemoglobin, hyperlipidemia, and atherosclerosis. Subsequently, these factors were considered as independent variables, while the occurrence of diabetic foot was considered as the dependent variable in a Logistic regression model. The results indicated that the above risk factors were independent influencing factors for diabetic foot (all P<0.05). See Table 3.

Table 3.

Logistic analysis of risk factors for predicting diabetic foot

Factor OR P 95% CI
Male 1.780 0.003 1.011-1.882
Smoking 1.395 0.017 1.033-1.906
Duration of diabetes (year) 3.885 0.000 1.883-5.377
Glycated hemoglobin (%) 2.441 0.001 1.652-4.550
Hyperlipidemia 1.893 0.002 1.261-3.344
Atherosclerosis 2.074 0.000 1.736-2.193

Note: CI: Confidence Interval.

Construction of nomogram prediction model for diabetic foot through multivariate analysis

A nomogram prediction model for early warning of diabetic foot associated with type 2 diabetes was constructed using the six independent factors. As shown in the Figure 2, in practical application, each point can be determined by drawing a line upwards from the straight line corresponding to each predictive variable on the axis, and the total score can be calculated by summing up the points. By drawing a straight line downwards on the total score axis, the probability of developing diabetic foot associated with type 2 diabetes can be calculated.

Figure 2.

Figure 2

A nomogram prediction model for the risk of diabetic foot in diabetes patients. DF: diabetic foot; HbA1c: hemoglobin A1C.

Validation of the nomogram prediction model for diabetes foot

The findings revealed that the calibration curve of the constructed nomogram prediction model exhibited good consistency. The AUC of the nomogram prediction model was 0.804, with a sensitivity and specificity of 75.3% and 74.4%, respectively. The Harrell’s C-index of the prediction model was 0.803 (95% CI: 0.762-0.845), indicating good discriminability of the model. Besides, the decision curve analysis (DCA) showed that the threshold for the nomogram diabetic foot model was >0.675, providing net clinical benefit. See Figures 3, 4 and 5.

Figure 3.

Figure 3

Calibration curve of the nomogram model for the risk of diabetic foot in diabetes patients. DF: diabetic foot.

Figure 4.

Figure 4

ROC curve of the variables associated with diabetic foot in diabetes patients. AUC: area under curve; ROC: receiver operating characteristic.

Figure 5.

Figure 5

Decision curve of the variables associated with diabetic foot in diabetic patients.

Discussion

Diabetic foot is one of the serious complications associated with diabetes, which impacts patients’ quality of life and may result in amputation [10,11]. Research has shown that diabetes-related factors account for over 80% of non-traumatic foot amputations, highlighting diabetes as the most important cause of foot injuries [12]. Furthermore, epidemiological surveys have indicated a prevalence of diabetic foot of nearly 10% in the diabetic population [13]. Therefore, diabetic foot is an important target for intervention in diabetes treatment, and it is of great significance to identify relevant risk factors from baseline data and implement intervention measures to improve the overall diagnosis and treatment of diabetic foot.

In this study, the baseline data of patients with diabetic foot and non-diabetic foot demonstrated that male sex, smoking, duration of diabetes, glycated hemoglobin, hyperlipidemia, and atherosclerosis were independent influencing factors for diabetes foot. Based on these risk factors, a nomogram prediction model for diabetic foot was developed. It showed good predictive performance from the results of ROC and DCA. Application of this model in clinical practice could effectively reduce the incidence of diabetic foot and improve the prognosis of such patients.

Diabetic foot is closely related to male sex. This study revealed a higher proportion of male patients with diabetic foot, which may be attributed to men engaging in physical activities that lead to increased energy consumption. Moreover, men tend to have poorer compliance, resulting in reduced diabetes control rates and subsequently leading to the diabetic foot [14-16]. Smoking has been proven to be closely associated with the occurrence of diabetic foot. Substances presenting in tobacco, when burned at high temperatures, can increase insulin resistance, leading to poor blood glucose control. Furthermore, smoking exacerbates endothelial cell damage, causing endothelial dysfunction and affecting blood flow to the feet [17,18]. The duration of diabetes is a major risk factor for diabetic foot, primarily due to long-term exposure of endothelial cells to a high-glucose environment, reflecting on continuous endothelial damage to the blood vessels in foot and subsequent vascular occlusion and impaired blood flow [19-21]. Glycated hemoglobin reflects blood glucose control over the past three months. If a patient has high levels of glycated hemoglobin, it indicates poor blood glucose control, which in turn activates various pathways such as the polyol pathway, advanced glycation end products, and hexosamine pathway, further exacerbating endothelial cell damage in the lower limb blood vessels and worsening vascular injury [22,23]. Hyperlipidemia and atherosclerosis are local pathologic changes that occur after vascular damage. Given the small size of foot blood vessels, once atherosclerosis occurs, it can lead to blockage or even occlusion, resulting in ischemia, hypoxia, and subsequently leading to diabetic foot [24,25]. Hyperlipidemia can further reduce blood flow to the feet by exacerbating vascular atherosclerosis, thereby worsening the condition of diabetic foot [26,27]. However, the author found that fasting blood glucose and blood cell analysis were not risk factors for diabetic foot, which may be associated with their higher variability and differ from the conclusions of other studies, possibly due to the sample size.

The construction of a nomogram prediction model for diabetic foot in this study helps clinicians effectively assess the patients’ condition based on their baseline characteristics. It also facilitates patients and their families in understanding their own condition and the risk of developing diabetic foot, enabling precise intervention measures based on individual characteristics.

Internal validation and clinical prediction performance evaluation further assessed the detection performance of the nomogram model. The results showed that the model for diabetic foot has desirable accuracy and clinical utility. However, this study has certain limitations. First, it is a single-center study, which limits the diversity and generalizability of the included individuals. Further research with larger sample sizes and multiple centers is needed to improve the model. Secondly, the nomogram prediction model has not been externally validated with an independent dataset, which may affect the reliability of the study results and requires further investigation.

Finally, Chinese residents have certain lifestyle habits that vary throughout the year. For instance, during winter, people tend to have longer intervals between showers compared to summer. Moreover, there is an inability to define prolonged sitting accurately. Therefore, it is not currently feasible to incorporate them into our study. Additionally, the lack of imaging data results in the loss of some predictive functions related to imaging indicators. Therefore, it is necessary to strengthen the provision of clinical data.

In conclusion, this study constructed a nomogram model for predicting diabetic foot in diabetes patients based on factors such as gender, smoking history, duration of diabetes, glycated hemoglobin, hyperlipidemia, and atherosclerosis. The model has good predictive value for diabetic patients with foot complications and has high clinical utility.

Acknowledgements

The research was supported by 2021 Guangdong science and technology special fund (210716116901047).

Disclosure of conflict of interest

None.

References

  • 1.Cole JB, Florez JC. Genetics of diabetes mellitus and diabetes complications. Nat Rev Nephrol. 2020;16:377–390. doi: 10.1038/s41581-020-0278-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Petersmann A, Müller-Wieland D, Müller UA, Landgraf R, Nauck M, Freckmann G, Heinemann L, Schleicher E. Definition, classification and diagnosis of diabetes mellitus. Exp Clin Endocrinol Diabetes. 2019;127:S1–S7. doi: 10.1055/a-1018-9078. [DOI] [PubMed] [Google Scholar]
  • 3.Agashe S, Petak S. Cardiac autonomic neuropathy in diabetes mellitus. Methodist Debakey Cardiovasc J. 2018;14:251–256. doi: 10.14797/mdcj-14-4-251. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Brocco E, Ninkovic S, Marin M, Whisstock C, Bruseghin M, Boschetti G, Viti R, Forlini W, Volpe A. Diabetic foot management: multidisciplinary approach for advanced lesion rescue. J Cardiovasc Surg (Torino) 2018;59:670–684. doi: 10.23736/S0021-9509.18.10606-9. [DOI] [PubMed] [Google Scholar]
  • 5.Coffey L, Mahon C, Gallagher P. Perceptions and experiences of diabetic foot ulceration and foot care in people with diabetes: a qualitative meta-synthesis. Int Wound J. 2019;16:183–210. doi: 10.1111/iwj.13010. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 6.Dayya D, O’Neill OJ, Huedo-Medina TB, Habib N, Moore J, Iyer K. Debridement of diabetic foot ulcers. Adv Wound Care (New Rochelle) 2022;11:666–686. doi: 10.1089/wound.2021.0016. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7.Wu J, Zhang H, Li L, Hu M, Chen L, Xu B, Song Q. A nomogram for predicting overall survival in patients with low-grade endometrial stromal sarcoma: a population-based analysis. Cancer Commun (Lond) 2020;40:301–312. doi: 10.1002/cac2.12067. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8.Yu C, Zhang Y. Establishment of prognostic nomogram for elderly colorectal cancer patients: a SEER database analysis. BMC Gastroenterol. 2020;20:347. doi: 10.1186/s12876-020-01464-z. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9.Khan RMM, Chua ZJY, Tan JC, Yang Y, Liao Z, Zhao Y. From pre-diabetes to diabetes: diagnosis, treatments and translational research. Medicina (Kaunas) 2019;55:546. doi: 10.3390/medicina55090546. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10.Iatcu CO, Steen A, Covasa M. Gut microbiota and complications of type-2 diabetes. Nutrients. 2021;14:166. doi: 10.3390/nu14010166. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Zhang Z, Zhang L, Xu H. Effect of astragalus polysaccharide in treatment of diabetes mellitus: a narrative review. J Tradit Chin Med. 2019;39:133–138. [PubMed] [Google Scholar]
  • 12.Mariadoss AVA, Sivakumar AS, Lee CH, Kim SJ. Diabetes mellitus and diabetic foot ulcer: etiology, biochemical and molecular based treatment strategies via gene and nanotherapy. Biomed Pharmacother. 2022;151:113134. doi: 10.1016/j.biopha.2022.113134. [DOI] [PubMed] [Google Scholar]
  • 13.Pourkazemi A, Ghanbari A, Khojamli M, Balo H, Hemmati H, Jafaryparvar Z, Motamed B. Diabetic foot care: knowledge and practice. BMC Endocr Disord. 2020;20:40. doi: 10.1186/s12902-020-0512-y. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Ciarambino T, Crispino P, Leto G, Mastrolorenzo E, Para O, Giordano M. Influence of gender in diabetes mellitus and its complication. Int J Mol Sci. 2022;23:8850. doi: 10.3390/ijms23168850. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 15.Coregliano-Ring L, Goia-Nishide K, Rangel ÉB. Hypokalemia in diabetes mellitus setting. Medicina (Kaunas) 2022;58:431. doi: 10.3390/medicina58030431. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Shepard BD. Sex differences in diabetes and kidney disease: mechanisms and consequences. Am J Physiol Renal Physiol. 2019;317:F456–F462. doi: 10.1152/ajprenal.00249.2019. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Larsson SC, Burgess S. Appraising the causal role of smoking in multiple diseases: a systematic review and meta-analysis of Mendelian randomization studies. EBioMedicine. 2022;82:104154. doi: 10.1016/j.ebiom.2022.104154. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Driva S, Korkontzelou A, Tonstad S, Tentolouris N, Katsaounou P. The effect of smoking cessation on body weight and other metabolic parameters with focus on people with type 2 diabetes mellitus. Int J Environ Res Public Health. 2022;19:13222. doi: 10.3390/ijerph192013222. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Ferrari SL, Abrahamsen B, Napoli N, Akesson K, Chandran M, Eastell R, El-Hajj Fuleihan G, Josse R, Kendler DL, Kraenzlin M, Suzuki A, Pierroz DD, Schwartz AV, Leslie WD Bone and Diabetes Working Group of IOF. Diagnosis and management of bone fragility in diabetes: an emerging challenge. Osteoporos Int. 2018;29:2585–2596. doi: 10.1007/s00198-018-4650-2. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Jun MH, Ku B, Kim J, Kim KH, Kim JU. Mediation effect of the duration of diabetes mellitus on the decrease in bioimpedance phase angles in ethnically Korean people: a multicenter clinical study. J Diabetes Investig. 2021;12:790–802. doi: 10.1111/jdi.13399. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Siddiqui K, George TP, Joy SS, Alfadda AA. Risk factors of chronic kidney disease among type 2 diabetic patients with longer duration of diabetes. Front Endocrinol (Lausanne) 2022;13:1079725. doi: 10.3389/fendo.2022.1079725. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Klonoff DC. Hemoglobinopathies and hemoglobin A1c in diabetes mellitus. J Diabetes Sci Technol. 2020;14:3–7. doi: 10.1177/1932296819841698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Chume FC, Freitas PAC, Schiavenin LG, Pimentel AL, Camargo JL. Glycated albumin in diabetes mellitus: a meta-analysis of diagnostic test accuracy. Clin Chem Lab Med. 2022;60:961–974. doi: 10.1515/cclm-2022-0105. [DOI] [PubMed] [Google Scholar]
  • 24.Wei X, Wen Y, Zhou Q, Feng X, Peng FF, Wang N, Wang X, Wu X. Hyperlipidemia and mortality associated with diabetes mellitus co-existence in chinese peritoneal dialysis patients. Lipids Health Dis. 2020;19:234. doi: 10.1186/s12944-020-01405-5. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25.Wang S, Ren H, Zhong H, Zhao X, Li C, Ma J, Gu X, Xue Y, Huang S, Yang J, Chen L, Chen G, Qu S, Liang J, Qin L, Huang Q, Peng Y, Li Q, Wang X, Zou Y, Shi Z, Li X, Li T, Yang H, Lai S, Xu G, Li J, Zhang Y, Gu Y, Wang W. Combined berberine and probiotic treatment as an effective regimen for improving postprandial hyperlipidemia in type 2 diabetes patients: a double blinded placebo controlled randomized study. Gut Microbes. 2022;14:2003176. doi: 10.1080/19490976.2021.2003176. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26.Yuan T, Yang T, Chen H, Fu D, Hu Y, Wang J, Yuan Q, Yu H, Xu W, Xie X. New insights into oxidative stress and inflammation during diabetes mellitus-accelerated atherosclerosis. Redox Biol. 2019;20:247–260. doi: 10.1016/j.redox.2018.09.025. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Høilund-Carlsen PF, Piri R, Madsen PL, Revheim ME, Werner TJ, Alavi A, Gerke O, Sturek M. Atherosclerosis burdens in diabetes mellitus: assessment by PET imaging. Int J Mol Sci. 2022;23:10268. doi: 10.3390/ijms231810268. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from American Journal of Translational Research are provided here courtesy of e-Century Publishing Corporation

RESOURCES